ArriVent BioPharma, Inc.

ArriVent Biopharma, Inc. (Nasdaq: AVBP) is a clinical-stage biopharmaceutical company dedicated to identifying, developing, and commercializing differentiated medicines for patients with cancer. The company's website is www.arriventbio.com.

ArriVent's lead product candidate is firmonertinib, an investigational epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor being developed for non-small cell lung cancer patients with various EGFR mutations. The company licensed worldwide development and commercialization rights to firmonertinib from Shanghai Allist Pharmaceuticals in 2021, excluding greater China. Firmonertinib is currently approved and commercially distributed in China for first-line treatment of locally advanced or metastatic NSCLC patients with classical EGFR mutations. ArriVent is conducting two pivotal Phase 3 clinical trials: the FURVENT trial in first-line patients with exon 20 insertion mutations, with topline data expected in mid-2026, and the ALPACCA trial in first-line patients with P-loop and alpha-c-helix compressing mutations. The company received Breakthrough Therapy Designation from the FDA in October 2023 for firmonertinib in first-line EGFR-mutant NSCLC with exon 20 insertion mutations.

Beyond firmonertinib, ArriVent is advancing a pipeline of next-generation antibody-drug conjugates through multiple collaborations. The company has research collaborations with Aarvik Therapeutics and Alphamab Biopharmaceuticals to discover and develop novel ADCs, and licensed ARR-217, a CDH17-targeting ADC for gastrointestinal cancers, from Lepu Biopharma in January 2025. ARR-217 is currently in Phase 1 clinical development.

ArriVent's business strategy focuses on sourcing innovative oncology therapeutics globally, with particular emphasis on compounds originally developed in China for potential commercialization in the United States, European Union, and other jurisdictions. The company leverages its team's extensive experience in drug development, regulatory affairs, and business development to build a competitive pipeline of differentiated cancer therapeutics. Since inception in 2021, ArriVent has established multiple licensing agreements and collaborations to expand its oncology portfolio across various therapeutic modalities and cancer indications.